Regencell Bioscience Holdings Limited (RGC) earnings
Regencell Bioscience Holdings Limited (RGC) reported net income of -$11.70M in fiscal 2026 (the year ended June 30, 2026). Figures as of 18 Nov 2026, 10:34 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Earnings (net income), fiscal 2026
- -$11.70M
- Highest on record
- -$390.99Kfiscal 2019
- Lowest on record
- -$11.70Mfiscal 2026
- Fiscal years on record
- 72019–2026
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Regencell Bioscience Holdings Limited earnings, in more detail
Across the 7 fiscal years on record (2019–2026), the highest was -$390.99K in fiscal 2019 and the lowest -$11.70M in fiscal 2026.
Earnings (net income) by fiscal year
Regencell Bioscience Holdings Limited earnings, year by year
| Fiscal year | Earnings (net income) | Change | Year ended |
|---|---|---|---|
| 2026 | -$11.70M | — | |
| 2024 | -$4.30M | — | |
| 2023 | -$5.87M | — | |
| 2022 | -$7.45M | — | |
| 2021 | -$1.35M | — | |
| 2020 | -$812.37K | — | |
| 2019 | -$390.99K | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.
How to read it
Compare it across years rather than in isolation — one-off gains and write-downs can swing a single year a long way.
Regencell Bioscience Holdings Limited, figure by figure
- Regencell Bioscience Holdings Limited market cap
- Regencell Bioscience Holdings Limited revenue
- Regencell Bioscience Holdings Limited earnings per share (EPS)
- Regencell Bioscience Holdings Limited P/E ratio
- Regencell Bioscience Holdings Limited P/S ratio
- Regencell Bioscience Holdings Limited P/B ratio
- Regencell Bioscience Holdings Limited free cash flow
- Regencell Bioscience Holdings Limited operating margin
- Regencell Bioscience Holdings Limited dividend
- Regencell Bioscience Holdings Limited shares outstanding
- Regencell Bioscience Holdings Limited total debt
- Regencell Bioscience Holdings Limited cash on hand
- Regencell Bioscience Holdings Limited total assets
- Regencell Bioscience Holdings Limited return on equity (ROE)
- Regencell Bioscience Holdings Limited return on invested capital (ROIC)
Regencell Bioscience Holdings Limited (RGC) overview: price, valuation and scorecard
Regencell Bioscience Holdings Limited earnings: questions and answers
What is Regencell Bioscience Holdings Limited's net income?
Regencell Bioscience Holdings Limited (RGC) reported net income of -$11.70M in fiscal 2026 (the year ended June 30, 2026).
What are the highest and lowest net income figures on record for Regencell Bioscience Holdings Limited?
Across the 7 fiscal years on record (2019–2026), the highest was -$390.99K in fiscal 2019 and the lowest -$11.70M in fiscal 2026.
How is Regencell Bioscience Holdings Limited's net income calculated?
Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement. For Regencell Bioscience Holdings Limited it is on record here for 7 fiscal years, 2019 to 2026.
Fiscal years are named for the calendar year they end in.
Learn: earnings
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Regencell Bioscience Holdings Limited (RGC) earnings”, data as of 18 November 2026. https://funkfolio.com/stock/RGC/earnings
Underlying data: the company's filings with the SEC and Yahoo Finance.